Literature DB >> 26214054

Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis.

Davy Vancampfort1, Alex J Mitchell, Marc De Hert, Pascal Sienaert, Michel Probst, Roselien Buys, Brendon Stubbs.   

Abstract

OBJECTIVE: This systematic review and meta-analysis assessed the prevalence and predictors of type 2 diabetes mellitus (T2DM) in people with bipolar disorder. We also compared the prevalence of T2DM in people with bipolar disorder versus age- and gender-matched healthy controls. DATA SOURCES: PubMed, EMBASE, PsycARTICLES, and CINAHL were searched from inception till October 23, 2014 using the medical subject headings terms bipolar disorder AND diabetes OR glucose. There was no language restriction. Observational studies including retrospective, cross-sectional, and prospective designs were eligible if they included participants with bipolar disorder diagnosed according to recognized diagnostic criteria (DSM or ICD). STUDY SELECTION: Nineteen studies were included (n = 18,060; 54.8% male). DATA EXTRACTION: Two independent authors extracted data in accordance with the meta-analysis of observational studies in epidemiology guidelines and PRISMA statement. A random effects meta-analysis was utilized.
RESULTS: The overall prevalence of T2DM was 9.4% (95% CI, 6.5%-12.7%). Compared with age- and gender-matched controls (n = 783,049; 48.7% male), people with bipolar disorder (n = 6,595; 48.6% male) had double the risk of T2DM (relative risk = 1.98; 95% CI, 1.6-2.4, P < .001). No significant moderators were found. In an exploratory regression analysis, the variance in T2DM prevalence in the background population was associated with the variance in T2DM prevalence in people with bipolar disorder (5 studies, n = 4,983) (r(2) = 0.85, t = 4.09, P = .03).
CONCLUSIONS: T2DM is significantly more common in people with bipolar disorder than in healthy controls of similar age and sex. The current meta-analysis furthermore indicates that changes in food, built, and social environments are needed in order to curb the diabetes epidemic in this high-risk population. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26214054     DOI: 10.4088/JCP.14r09635

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  24 in total

1.  Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes.

Authors:  Rodrigo B Mansur; Gabriel R Fries; Mehala Subramaniapillai; Sophia Frangou; Fernanda G De Felice; Natalie Rasgon; Bruce McEwen; Elisa Brietzke; Roger S McIntyre
Journal:  J Psychiatr Res       Date:  2018-10-27       Impact factor: 4.791

2.  The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders.

Authors:  Rodrigo B Mansur; Gabriel R Fries; Alisson P Trevizol; Mehala Subramaniapillai; Julie Lovshin; Kangguang Lin; Maj Vinberg; Roger C Ho; Elisa Brietzke; Roger S McIntyre
Journal:  Eur Neuropsychopharmacol       Date:  2018-11-06       Impact factor: 4.600

3.  Increased risk of fracture in patients with bipolar disorder: a nationwide cohort study.

Authors:  Chih-Chao Hsu; Yi-Chao Hsu; Kuang-Hsi Chang; Chang-Yin Lee; Lee-Won Chong; Yu-Chiao Wang; Chung-Y Hsu; Chia-Hung Kao
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-05-30       Impact factor: 4.328

4.  Neural, Hormonal, and Cognitive Correlates of Metabolic Dysfunction and Emotional Reactivity.

Authors:  Tovah Wolf; Vera Tsenkova; Carol D Ryff; Richard J Davidson; Auriel A Willette
Journal:  Psychosom Med       Date:  2018-06       Impact factor: 4.312

Review 5.  Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews.

Authors:  Nanna Lindekilde; Stine H Scheuer; Femke Rutters; Lenette Knudsen; Mathias Lasgaard; Katrine H Rubin; Jan Erik Henriksen; Mika Kivimäki; Gregers S Andersen; Frans Pouwer
Journal:  Diabetologia       Date:  2021-11-29       Impact factor: 10.122

6.  High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder.

Authors:  Virginio Salvi; Francesco Barone-Adesi; Virginia D'Ambrosio; Umberto Albert; Giuseppe Maina
Journal:  Psychopharmacology (Berl)       Date:  2015-09-26       Impact factor: 4.530

7.  Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.

Authors:  Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs
Journal:  World Psychiatry       Date:  2016-06       Impact factor: 49.548

8.  Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.

Authors:  Masuma Pervin Mishu; Eleonora Uphoff; Faiza Aslam; Sharad Philip; Judy Wright; Nilesh Tirbhowan; Ramzi A Ajjan; Zunayed Al Azdi; Brendon Stubbs; Rachel Churchill; Najma Siddiqi
Journal:  Cochrane Database Syst Rev       Date:  2021-02-16

9.  Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin.

Authors:  Rodrigo B Mansur; Francheska Delgado-Peraza; Mehala Subramaniapillai; Yena Lee; Michelle Iacobucci; Flora Nasri; Nelson Rodrigues; Joshua D Rosenblat; Elisa Brietzke; Victoria E Cosgrove; Nicole E Kramer; Trisha Suppes; Charles L Raison; Andrea Fagiolini; Natalie Rasgon; Sahil Chawla; Carlos Nogueras-Ortiz; Dimitrios Kapogiannis; Roger S McIntyre
Journal:  J Psychiatr Res       Date:  2020-12-04       Impact factor: 4.791

10.  Investigation of glycaemic traits in psychiatric disorders using Mendelian randomisation revealed a causal relationship with anorexia nervosa.

Authors:  Danielle M Adams; William R Reay; Michael P Geaghan; Murray J Cairns
Journal:  Neuropsychopharmacology       Date:  2020-09-13       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.